US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch of its Noxafil (posaconazole) in China. Noxafil is an antifungal agent used to prevent invasive aspergillosis and candida infection and treat invasive aspergillosis.
Drug Profile and Dosage Forms
Noxafil is a next-generation triazole antifungal drug with three dosage forms. Currently, three dosage forms of posaconazole oral suspension, enteric-coated tablets, and injection have been approved for marketing in China. The posaconazole oral suspension can be used to prevent invasive aspergillus and candida infections and treat oropharyngeal candidiasis. The posaconazole enteric-coated tablets and posaconazole injection can be used to prevent invasive aspergillus and candida infections and treat invasive aspergillosis.
Market Access and Reimbursement
Posaconazole oral suspension was included in the National Reimbursement Drug List (NRDL) in 2021. In 2019, posaconazole was included in the first batch of drugs encouraged for generic development in China, where Aosaikang had its own version approved. The market launch of Noxafil in China positions MSD to further expand its presence in the antifungal market, addressing significant unmet medical needs and improving patient outcomes.-Fineline Info & Tech
